Oculus
websites contain information about products,
which may or may not be
available in any particular country, and if applicable,
may have received
approval or market clearance by a governmental
regulatory body for different
indications and restrictions in different countries.
Each country has
specific laws, regulations and medical practices
governing the communication
of medical or other information about medical products
on the Internet.
Nothing herein should be construed as a solicitation
or promotion for any
product or for an indication for any product, which
is not authorized by the
laws and regulations of the country where the reader
resides.
This site may contain information
on medical and health-related topics. This
information is not meant to be a substitute for
the advice provided by your
own physician or other medical professional.
You should not use this
information for diagnosing a health problem or
disease but should always
consult your own physician.
These press releases about Oculus Incorporated
are sorted by date, with the most recent at the
top. You will need the free Adobe®
Reader® to view the PDFs. |
Current
Press Releases
.....................................................................................
August 7,
2008
Oculus
Innovative Sciences to Present at Canaccord Adams
28th Annual Global Growth Conference
August 5,
2008
Oculus
Innovative Sciences Reports 59% Increase in First
Quarter Product Revenue
July 29, 2008
Oculus
Innovative Sciences Announces Fiscal First Quarter
Financial Results and Corporate Update Release
and Conference Call
July 16, 2008
Oculus
Innovative Sciences' CEO and Founder Named One
of Pharmaceutical Executive's 2008 "Emerging
Pharma Leaders"
July 1, 2008
Oculus
Innovative Sciences Announces Positive Results
from Abstract Evaluating the Use of Microcyn® Technology
in Treatment of Atopic Dermatitis
June 23, 2008
Oculus
Innovative Sciences Announces Agreement With Bayer
(Sichuan) Animal Health Co. Ltd. for Development
of Microcyn® Technology Use in Chinese Animal
Market
June 19, 2008
Oculus
Innovative Sciences Announces Agreement with
Bayer Australia Limited for Development of Microcyn® Technology
Use in Australian Animal Market
June 17, 2008
Oculus
Innovative Sciences Announces Development of
Microcyn®-Based Hydrogel Formulation
June 16, 2008
Oculus
Innovative Sciences Announces Breakthrough Antimicrobial
Formulation for Over-The-Counter Non-Wound Market
to be Launched in U.S. Without Pre-Approval by
the FDA
June 11, 2008
Oculus
Innovative Sciences Announces Fiscal Fourth Quarter
and Full Year 2008 Financial Results and Corporate
Update
June 5, 2008
Oculus
Innovative Sciences Announces Fiscal Fourth Quarter
and Full Year 2008 Financial Results and Corporate
Update Release and Conference Call
June 4, 2008
Oculus
Innovative Sciences Files for Patent Protection
on Breakthrough Wound Care Device to Accelerate
Wound Healing
June 2, 2008
Oculus
Innovative Sciences Announces Market Assessment
of Near-Term Commercialization Opportunities in
the United States for Dermacyn™ Wound Care
May 28, 2008
Oculus
Innovative Sciences Announces Publication of Microcyn® Technology
Post-Caesarean Section Wound Study in Indian Medical
Gazette
May 15, 2008
Oculus
Innovative Sciences to Participate in Third Congress
of the World Union of Wound Healing Societies in
Toronto
May 5, 2008
Oculus
Innovative Sciences Announces Initial Chinese Commercialization
Plan for Launch of Microcyn® Technology
April 23,
2008
Oculus
Innovative Sciences Appoints Michelle Carpenter,
JD, RAC, as Vice President of Regulatory Affairs
and Quality
April 17,
2008
Oculus
Innovative Sciences' CEO and Founder Hoji Alimi
Featured on NASDAQ CEO Signature Series
April 15,
2008
Oculus
Innovative Sciences Announces Publication of Microcyn® Technology
Diabetic Wound Study in Journal of College of Physicians
and Surgeons Pakistan
March 28,
2008
Oculus
Innovative Sciences, Inc., Announces $13.9 Million
Securities Offering
March 27,
2008
Oculus
Innovative Sciences Receives Chinese SFDA Regulatory
Approval of Microcyn® Technology
March 17, 2008
Oculus
Innovative Sciences Announces Positive Results From
Three Abstracts Evaluating the Use of Microcyn®
Technology in Diabetic Foot Ulcers
March 14, 2008
Oculus
Innovative Sciences Announces Additional Phase II
Data for Microcyn® Technology in Mildly Infected
Diabetic Foot Ulcers
March 12,
2008
Oculus
Innovative Sciences Announces Acceptance of Three
Abstracts on the use of Microcyn® Technology
in Diabetic Foot Ulcers by DFCon 08
March 11,
2008
Oculus
Innovative Sciences to Announce Additional Phase
II Data and Data from Two Recent International
Studies at DFCon 08
February
27, 2008
Oculus
Innovative Sciences Schedules Conference Call
Today to Discuss Positive Top-Line Phase II Data
with Microcyn® Technology in Mildly Infected
Diabetic Foot Ulcers
February
27, 2008
Oculus
Innovative Sciences Announces Positive Top-Line
Phase II Data with Microcyn® Technology in
Mildly Infected Diabetic Foot Ulcers
February
14, 2008
Oculus
Innovative Sciences to Present at the Roth Capital
Partners 20th Annual OC Growth Stock Conference
February
7, 2008
Oculus
Innovative Sciences Announces Fiscal Third Quarter
2008 Quarterly Results and Clinical Update
February
5, 2008
Oculus
Schedules Fiscal Third Quarter 2008 Financial
Results Release and Conference Call
January
29, 2008
Oculus
Innovative Sciences Announces Agreement with
Animal Health International for North American
Distribution of Microcyn®-Based Vetericyn™ Wound
Spray
January
24, 2008
Oculus
Innovative Sciences Awarded Damages by Federal
Court in Intellectual Property Rights Litigation
January
22, 2008
Top-Line
Data from Oculus Innovative Sciences' Phase II
Trial to Be Presented at DFCon 08 (Diabetic Foot
Global Conference) on March 14, 2008
January
17, 2008
Oculus
Innovative Sciences, Inc. Appoints Gregg Alton
to its Board of Directors
January
3, 2008
Oculus
Innovative Sciences Completes Patient Treatment
and Follow-up in Its Phase II Clinical Trial
in Mildly Infected Diabetic Foot Ulcers
December
18, 2007
Oculus
Innovative Sciences Announces Completion of
Two Randomized Controlled Clinical Trials of
Microcyn® Technology in China
December
5, 2007
Oculus
Innovative Sciences Completes Enrollment of Phase
II Trial of Microcyn® Technology in Treatment
of Mildly Infected Diabetic Foot Ulcers
November
19, 2007
Oculus
Innovative Sciences Wins Federal Court Ruling
in Intellectual Property Rights Litigation
November
12, 2007
Oculus
Innovative Sciences Announces Fiscal
Second Quarter 2008 Quarterly Results
and Clinical Update
November
8, 2007
Oculus
Innovative Sciences Schedules Fiscal
Second Quarter 2008 Financial Results
Release and Conference Call
November
1, 2007
Oculus
Innovative Sciences to Present at SMH
Capital Markets Investor Growth Conference
October
30, 2007
Oculus
Innovative Sciences to Present at Acumen
BioFin 9th Annual Healthcare Conference
October
3, 2007
Oculus
Innovative Sciences to Present at 4th
Annual BIO InvestorForum Conference
September
17, 2007
Oculus
Innovative Sciences Microcyn Technology
Data to be Presented by Researchers
at the 47th Interscience Conference
on Antimicrobial Agents and Chemotherapy
September
17, 2007
Oculus
Innovative Sciences Provides Update
of Phase II Study for Microcyn® Technology
in Mildly Infected Diabetic Foot Ulcers
September
14, 2007
Oculus
Innovative Sciences to Conduct Conference
Call Update on Phase II Study of Microcyn® Technology
in Mildly Infected Diabetic Foot Ulcers
September
6, 2007
Oculus
Innovative Sciences to Present at First
Albany Capital Regenerative Technologies
Conference
August 29,
2007
Oculus
Innovative Sciences to Present at Roth
Capital Partners 2007 New York Conference
August 9,
2007
Oculus
Innovative Sciences Announces Fiscal
First Quarter 2008 Financial Results
August 8,
2007
Oculus
Innovative Sciences Announces $10.1
Million Private Placement of Common
Stock
August 3,
2007
Oculus
Innovative Sciences Schedules Fiscal
First Quarter 2008 Financial Results
Release and Conference Call
June 26,
2007
Oculus
Innovative Sciences Announces Results
From Anti-Inflammatory Study Using
Microcyn® Technology
June 18,
2007
Oculus
Innovative Sciences Appoints Vice President
of Regulatory Affairs and Quality
June 13,
2007
Drug
Enhancement Company of America Licenses
Oculus' Microcyn®
Technology for Use in First Responder
''Pen-Like'' Applicator
June 7,
2007
Oculus
Announces Fiscal Fourth Quarter and
Full Year 2007 Financial Results
June 6,
2007
Oculus
Schedules Fiscal Fourth Quarter and
Full Year 2007 Financial Results Release
and Conference Call
Archived Press Releases
.....................................................................................
May 21,
2007
Oculus
Initiates Patient Enrollment in Phase II Study
of Microcyn®
Technology for Treatment of Mild Diabetic Foot Infections
May 14,
2007
Oculus
Innovative Sciences Microcyn® Technology
Presented in Poster at European Wound Management
Association Conference
May 9, 2007
Oculus
Innovative Sciences to Present at Rodman & Renshaw
Global Healthcare Conference
April 26,
2007
China
Bao Tai, Sinopharm and Lianhua Supermarkets
to Distribute Oculus' Microcyn®-Based Wound
Care Solution in China
April 25,
2007
Oculus
Innovative Sciences, Inc. Appoints Jay E. Birnbaum
to Its Board of Directors
March 29,
2007
Oculus
Announces Initial Sites for Phase II Clinical
Trial of Microcyn® Technology in Treatment
of Mild Diabetic Foot Infections
February
22, 2007
Oculus
Innovative Sciences Announces Fiscal Third
Quarter 2007 Results
January
24, 2007
Oculus
Innovative Sciences, Inc. Announces Initial Public
Offering
» Click
Here For More Archived Press Releases
|
Media
Coverage
.....................................................................................
August
1, 2008
FOX Business News:
America's Nightly Scoreboard
The following video is available in Windows®
Media Player, and RealPlayer®.
Click on the links below to view the videos in
your preferred format.
June
9, 2008
North Bay
Business Journal
Device
expected to greatly widen Oculus’ market
(PDF: 124 KB)
April
16, 2008
NASDAQ CEO
Signature Series: Interview with Hoji Alimi
The following video is available in Windows®
Media Player, and RealPlayer®.
Click on the links below to view the videos
in your preferred format.
February
27,
2008
Bloomberg
Oculus
Treatment Effective Against Diabetic Foot Infections
(PDF: 16 KB)
October
2007
Esquire
Esquire
100: Miracle Water
(PDF: 2.1 MB)
October
3, 2007
KGO-AM
810 News Talk
Hoji
Alimi speaks about the Microcyn® Technology
on KGO-AM 810 radio. Click to listen now.
Note: If you have problems
accessing the MP3 file, PC users may need to
right click on the the link and "Save
Target As." After you have saved the file,
open it in your preferred media player such
as Windows®
Media Player or RealPlayer®.
June
2007
'Miracle Water'
Offers Hope Against Infection
The following video is available in Apple®
QuickTime and Windows®
Media Player. Click on the links below
to view the videos in your preferred format.
June
2007
International
Immunopharmacology
Super-oxidized
solution inhibits IgE-antigen-induced degranulation
and cytokine release in mast cells
(PDF: 740 KB)
June
4, 2007
Diabetes
Health
It's
a Wash: New Antimicrobial Solution Called Microcyn
May Help Cure Diabetic Ulcers
May
24, 2007
The Daily
Mail
Scientists
create 'miracle water' that kills infections
and MRSA
(PDF: 228 KB)
May
24, 2007
BBC News
Firm
makes 'healing super-water'
(PDF: 84 KB)
May
23, 2007
BBC Radio
Five Live
Hoji
Alimi speaks about the Microcyn® Technology
on BBC Radio Five Live. Click to listen now.
Note: If you have problems accessing
the MP3 file, PC users may need to right click
on the the link and "Save Target As." After
you have saved the file, open it in your preferred
media player such as Windows® Media
Player or RealPlayer®
May
23, 2007
NewScientist.com
Bugs
struck down by 'super-oxidised' water
(PDF: 308 KB)
March
2007
The International
Journal of Lower Extremity Wounds
Clinical
Outcomes of Wide Postsurgical Lesions in the Infected Diabetic
Foot Managed...
(PDF: 232 KB)
September
2006
Wounds
Super-Oxidized
Solution (SOS) Therapy for Infected Diabetic
Foot Ulcers
(PDF: 256 KB)
August
2006
Podiatry
Today
Emerging
Innovations In Treatment
(PDF: 244 KB)
January
2006
Wounds
Clinical
Experience with a New, Stable, Super-Oxidized
Water in Wound Treatment
(PDF: 528 KB)
2005
Journal
of Hospital Infection
Microcyn®:
a novel super-oxidized water with neutral pH
and disinfectant activity
(PDF: 256 KB)
August
5, 2005
The New
York Times
As
New Products Arrive, Wound Care Sales Grow
(PDF: 64 KB)
June,
2005
Dermatology
Times
Super-oxidized
water kills bacteria; demonstrates potential
for healing
(PDF: 88 KB)
June
6, 2005
Outlook
India
H2O's
Healing Touch - Chronic wounds now find a cure,
courtesy Microcyn®
(PDF: 495 KB)
June
1, 2005
Coast to
Coast
Hoji
Alimi speaks about the Microcyn® Technology
on Coast to Coast AM radio. Click to listen now.
Note: If you have problems accessing
the MP3 file, PC users may need to right click
on the the link and "Save Target As." After
you have saved the file, open it in your preferred
media player such as Windows®
Media Player or RealPlayer®.
Oculus
on FOX News
The following video is available in Windows®
Media Player, and RealPlayer®.
Click on the links below to view the videos
in your preferred format.
May
17, 2005
Paul
Harvey mentions Microcyn® on his Tuesday
noon show. Listen now using Windows Media Player.
May
16, 2005
Super
Water Kills Bugs Dead -
A California company has figured out how to use
two simple materials....
(PDF: 65 KB)
March
26, 2005
'Ion
man' seeks to tap acceptance for his water solution -
A souped-up form of water has been overlooked as a killer
of lethal viruses and bacteria....
(PDF: 120 KB)
Oculus
on ABC News
The following video is available in Apple®
QuickTime, Windows®
Media Player, and RealPlayer®.
Click on the links below to view the videos
in your preferred format.
February
10, 2005
Read
What Forbes Magazine says about the Microcyn® Technology.
(PDF: 64 KB)
November
9, 2004
PESTICIDE.NET
- Super Oxidized Water Registered By EPA As A Hard-Surface
Disinfectant
(PDF: 120 KB) |
FAIR
USE NOTICE: These articles and news reports
may contain copyrighted material, the use of
which may or may not have been specifically
authorized by the copyright owner. This material
is being made available in efforts to advance
the understanding of scientific and medical
issues. It is believed that this constitutes
a 'fair use' of any such copyrighted material
as provided for in section 107 of the US Copyright
Law. In accordance with Title 17 U.S.C. Section
107, the material on this site is distributed
without profit to those who have expressed
a prior interest in receiving the included
information for research, comment, discussion
and educational purposes by visiting the Oculus
web site. If you wish to use copyrighted material
from these reports for purposes of your own
that go beyond 'fair use', you must obtain
permission from the copyright owner.
This web
page contains forward-looking statements that
involve risks and uncertainties. These forward-looking
statements relate to, among other things, regulatory
approvals, plans and timing for the introduction
of our products, statements about future market
conditions, supply and demand conditions, revenues,
gross margins, operating expenses, profits
and other expectations, intentions and plans
that are not historical fact.
Our expectations
as expressed at this web site depend upon our
ability to develop, manufacture, obtain regulatory
approval and supply and sell products that
meet defined specifications. When used, the
words "plan," "expect," "believe,"
and similar expressions generally identify forward-looking
statements. These statements reflect our current
expectations. They are subject to a number of
risks and uncertainties, including, but not limited
to, changes in technology and in the health sciences
market. In light of the many risks and uncertainties
surrounding this market, you should understand
that we cannot assure you that the forward-looking
statements contained herein will be realized. |
